SCHEDULE 13D/A
SCHEDULE 13D/ASchedule 13D ownership disclosure
Phathom Pharmaceuticals Inc
Common Stock, $0.0001 par value per share · CUSIP: 71722W107
Event date: 2025-05-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frazier Life Sciences Public Fund, L.P.Reported CIK 0001863769
Shares: 5,738,457.00 · Class: 8.0%
- FHMLSP, L.P.Reported CIK 0001879466
Shares: 5,738,457.00 · Class: 8.0%
- FHMLSP, L.L.C.Reported CIK 0001879465
Shares: 5,738,457.00 · Class: 8.0%
- Frazier Life Sciences Public Overage Fund, L.P.Reported CIK 0001913804
Shares: 1,531,870.00 · Class: 2.2%
- FHMLSP Overage, L.P.Reported CIK 0001963247
Shares: 1,531,870.00 · Class: 2.2%
- FHMLSP Overage, L.L.C.Reported CIK 0001963248
Shares: 1,531,870.00 · Class: 2.2%
- Frazier Life Sciences X, L.P.Reported CIK 0001790879
Shares: 48,203.00 · Class: 0.1%
- FHMLS X, L.P.Reported CIK 0001790880
Shares: 48,203.00 · Class: 0.1%
- FHMLS X, L.L.C.Reported CIK 0001790811
Shares: 48,203.00 · Class: 0.1%
- Frazier Life Sciences XI, L.P.Reported CIK 0001911592
Shares: 961,550.00 · Class: 1.4%
- FHMLS XI, L.P.Reported CIK 0001911580
Shares: 961,550.00 · Class: 1.4%
- FHMLS XI, L.L.C.Reported CIK 0001911623
Shares: 961,550.00 · Class: 1.4%
- Frazier Life Sciences IX, L.P.Reported CIK 0001720320
Shares: 5,827,415.00 · Class: 8.3%
- FHMLS IX, L.P.Reported CIK 0001782789
Shares: 5,827,415.00 · Class: 8.3%
- FHMLS IX, L.L.C.Reported CIK 0001782791
Shares: 5,827,416.00 · Class: 8.3%
- Frazier Life Sciences XII, L.P.Reported CIK 0002052255
Shares: 223,986.00 · Class: 0.3%
- FHMLS XII, L.P.Reported CIK 0002052246
Shares: 223,986.00 · Class: 0.3%
- FHMLS XII, L.L.C.Reported CIK 0002052177
Shares: 223,986.00 · Class: 0.3%
- James N. TopperReported CIK 0001341382
Shares: 14,429,990.00 · Class: 19.9%
- Patrick J. HeronReported CIK 0001365617
Shares: 14,346,419.00 · Class: 19.9%
- Albert ChaReported CIK 0001397906
Shares: 7,270,327.00 · Class: 10.1%
- James BrushReported CIK 0001865123
Shares: 7,270,327.00 · Class: 10.1%
- Daniel EstesReported CIK 0001702527
Shares: 1,185,536.00 · Class: 1.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-012779
- Form type
- SCHEDULE 13D/A
- Filer
- Frazier Life Sciences Public Fund, L.P.
- CIK
- CIK 1863769
- Filed
- May 13, 2025
- Reporting period
- May 09, 2025
- Description
- Schedule 13D beneficial ownership